A total of 24 monoclonal antibodies (MAbs) against the haemagglutinin (H) and the fusion protein (F) of rinderpest virus (RPV) were used to characterize their antigenic structure and biological properties, and to analyse natural variation in the envelope proteins of morbiUiviruses. The anti-H and anti-F MAbs defined seven and three distinct antigenic sites, respectively. The MAbs to six sites on H were able to neutralize the infectivity of RPV. The addition of guinea-pig complement or anti-mouse immunoglobulin increased the virus-neutralizing antibody titre of most of the anti-H MAbs, including those lacking neutralizing activity. One of the antigenic sites on H was conserved among morbilliviruses and the MAbs to this site had haemag-glutination inhibition activity against measles virus (MV). The remaining sites were specific for RPV and varied antigenically between strains of RPV. The anti-F MAbs lacked neutralizing activity, but two of the five MAbs did show activity in the presence of complement or anti-mouse immunoglobulin. On the whole, the antigenic sites on F were conserved in some strains of MV, but not in canine distemper virus. All of the sites on the surface proteins were sensitive to SDS and, although those on F were not affected by 2-mercaptoethanol, five of the seven sites on H were destroyed by it. These results suggest that the epitopes on the envelope proteins are conformation-dependent.
Introduction
Rinderpest virus (RPV) causes an acute, febrile and highly contagious disease in cattle and wild bovids in Africa, the Middle and Near East, and South Asia. In paramyxoviruses, the surface glycoproteins, haemagglutinin (H) and fusion protein (F), mediate virus attachment to and penetration of host cells (Scheid et al., 1972; Homma & Ohuchi, 1973) , and antibodies to these surface proteins probably play a key role in the development of immunity (Giraudon & Wild, 1985; Norrby et al., 1986) .
Protection against rinderpest using recombinant vaccinia viruses expressing the H or F gene of RPV has been described recently Barrett et al., 1989; Belsham et al., 1989; Tsukiyama et al., 1989) . However, detailed antigenic and functional analyses of these proteins have not been reported, with the exception of a few preliminary studies (Bhavani et al., 1989; Sugiyama et al., 1989) .
In this study, we have analysed the antigenic structures and functional properties of H and F of RPV (RPV-H and -F), and evaluated the antigenic variation in the envelope proteins of other morbilliviruses. 0001-0174 © 1991 SGM
Methods
Viruses. The lapinized (L) strain of RPV (Ishii et al., 1986) , at the 37th passage in Veto cells and the ninth passage in NA cells, a mouse neuroblastoma cell line, was used for the production of MAbs. Two strains (LA and RBOK) of RPV, five strains [FXNO, Hg, YSA, Hk and Snyder Hill (SH)] of canine distemper virus (CDV) and four strains [Edmonston (EDM), Toyoshima (TY), Ebihara (EBI) and Mantooth (MAN)] of measles virus (MV) were used in the indirect immunoftuorescent antibody (IFA) test; all were propagated in Vero cells. The RBOK vaccine strain (Plowright & Ferris, 1962) was obtained from the National Institute of Animal Health, Japan.
Monoclonal antibodies (MAbs) against RPV-H and -F. MAbs against RPV were prepared as described previously (Sugiyama et al., 1989) . Hybridoma cells producing anti-RPV MAbs were screened for antibody activity against the surface proteins using the membrane IFA test and then for activity against RPV-H or -F by the radioimmunoprecipitation assay (RIPA).
RIPA. When about 80% of an RPV-infected NA cell monolayer showed c.p.e., the cells were incubated in methionine-or glucose-free Eagle's MEM for 1 h, and labelled with 740 kBq]ml [35S]methionine (ICN Radiochemicals) for 4 h or 740 kBq/ml [3H]glucosamine (American Radiolabeled Chemicals) for 6 h, respectively. The RPVinfected NA cells were treated with tunicamycin (TM) by the method of Grubman et al. (1988) prior to radiolabelling to determine the reactivity of the MAbs with sugar residues on RPV-H. RIPA and electrophoresis were performed as described previously (Sugiyama et al., 1989) .
Competitive binding assay. Ascitic fluids were purified by affinity chromatography on an Affi-Gel Protein A column (Bio-Rad) using the MAPS buffer system (Bio-Rad) according to the manufacturer's instructions. The competitive binding assay was carried out as described previously (Sugiyama et al., 1989) .
ELISA. To prepare the antigen for ELISA, RPV-infected NA cells showing 80 to 90% c.p.e, were harvested. After freezing and thawing, and sonication at 20 kHz for 30 s, the cell extract was clarified by centrifugation at 3000 r.p.m, for 10 min. Antigen was incubated with 0.2% SDS or 10% 2-mercaptoethanol (2-ME) at 37 °C for 30 min; a one-fifth volume of 1 M-iodoacetamide was added to 2-ME-treated antigen and the mixture was dialysed against PBS. The treated antigens were diluted to a final concentration of 1:160 in 0.05 M-carbonate buffer pH 9.6 and absorbed onto a microtitre plate (Dynatech Laboratories) by incubation overnight at 4 °C (0.05 ml/well). The plate was rinsed once with PBS, coated with PBS containing 2% foetal bovine serum (0.1 ml/well) and incubated at 37 °C for 60 min. Ascitic fluids were serially diluted fourfold, starting at 1:800, and 0-05 ml of each dilution was put in a well. After incubation for 60 rain at 37 °C, the plate was washed five times in 0-15% Tween 20~PBS. The assay was processed using biotinylated anti-mouse IgG (EY Laboratories), peroxidase-streptavidin (Zymed Laboratories) and o-phenylenediamine. The ELISA titre was expressed as the reciprocal of the highest dilution of ascitic fluid giving an absorbance of greater than 0.5 at 490 nm.
IFA test. IFA and membrane IFA tests were performed as described previously (Sugiyama et al., 1989) .
Serological tests. Virus neutralization (VN) and complementrequiring neutralization (CRN) tests were 90 % plaque reduction assays on Veto cells, using the L strain of RPV as the challenge virus as described previously (Sugiyama et al., 1989) . The neutralizationenhancement (NE) test was conducted in a similar manner except that a 1:24 dilution of anti-mouse immunoglobulin (Cedarlane Laboratories) was added to the virus-antibody mixture instead of fresh guineapig serum. The haemagglutination inhibition (HI) test was carried out by testing the ascitic fluids using a commercial HA antigen (Toyoshima strain; Denka Seiken). The ascitic fluids were treated with kaolin and then absorbed to green monkey erythrocytes before testing. previously, precipitated proteins of both 45K and less than 24K, which corresponded to the F1 and F2 proteins, respectively ( Fig. 1 and 3) ; MAb 100 coprecipitated a 62K protein thought to be F0.
Results

Antigenic sites on RPV-H and -F
We tested a panel of MAbs in pairwise combinations in a competitive binding assay to identify topologically distinct antigenic sites on RPV-H or -F. The anti-H MAbs defined seven non-overlapping antigenic sites (I to VII) and one bridge site (III and IV) (Table 1) ; competition was non-reciprocal between sites V, VI and VII, i.e. binding of MAb 71 was inhibited by MAbs B-1 and E-l, but MAb B-1 and E-1 binding was not inhibited by MAb 71. The antigenic site which was recognized by anti-F MAb 100 was not identified because reproducible data were not obtained. The anti-F MAbs defined at least three different antigenic sites (A, B and C) ( Table 2) .
Specificity of the MAbs for RPV-H and -F
A total of 19 anti-H and five anti-F MAbs were obtained. All these MAbs reacted with the surface of RPV-infected cells, as demonstrated by capping in a membrane IFA test; one anti-F MAb (clone 100) showed very weak fluorescence. The specificity of these MAbs was determined by RIPA. Results from a representative subset of MAbs are shown in Fig. 1 . Of 24 MAbs, 19 MAbs, including those which had been newly isolated and two anti-H MAbs isolated in a previous study (Sugiyama et al., 1989) , reacted with a methionine-and glucosaminelabelled viral protein of Mr 76K to 80K ( Fig. 1 and 2) . The remaining MAbs, including two MAbs isolated
Biological activities of the MAbs against RPV-H and -F
The antibodies directed to epitopes on different functional domains of the surface proteins were thought to have different biological activities. Therefore, we tested a panel of MAbs using the VN, CRN, NE and HI tests ( Table 3 ). The anti-H MAbs which bound to sites II to VII neutralized virus infectivity, but MAb 50, to site I, showed only CRN and NE activity. Most of the MAbs to the epitopes in sites II, III, IV and VII showed strong VN activity, whereas those to sites V and VI had relatively weak activity. After the addition of guinea-pig complement or anti-mouse immunoglobulin to the VN assay 
Antigenic variation in H and F of morbilliviruses
As shown in Table 4 , only two (site V) anti-H MAbs were cross-reactive with all the morbillivirus strains tested, whereas the remaining MAbs were specific to RPV. All the MAbs to sites VI and VII, and five of those to sites II, III and IV, failed to cross-react with the RBOK strain of RPV. Moreover, two of the five MAbs to site VII failed to cross-react with the LA strain, the passage history of which was different to that of the L strain, and the remaining MAbs had lower IFA titres to the LA strain than to the L strain.
The MAbs to site A on RPV-F, with the exception of MAb 7-1 which did not react with the MAN strain, cross-reacted with MV. MAb 135, to site C, reacted only with the L and LA strains of RPV. The anti-F MAb to site B cross-reacted with two of the five strains of CDV and two of the four strains of MV tested; this MAb had lower IFA titres to CDV strains than to RPV and MV strains.
Structural requirement for each antigenic site
The MAbs were examined for their reactivity with TMtreated antigen using RIPA, to determine whether they were directed to the N-linked oligosaccharide chains on the envelope proteins of RPV. Anti-H MAbs precipitated a 76K to 80K protein from [3H]glucosaminelabelled, RPV-infected NA cell lysates, whereas this protein was not detected in TM-treated cell lysates (Fig.  2b) ; anti-H MAbs also precipitated a 76K to 80K RPV protein from methionine-labelled cells, but they precipitated a major 70K protein and a minor 54K protein from cells treated with TM ( Fig. 2a ). These findings indicated that asparagine-linked glycosylation was inhibited by TM.
The anti-F MAbs precipitated 54K and 45K proteins from TM-treated cells (Fig. 3) . The 70K and 54K II 6"5 6"5 5'9 2"9 S-I II 5"3 4"7 4'7 -29 III >/7"1 -6"5 -59 III, IV 5'3 -5"3 ld III, IV 5"3 -5"3 -19 IV 6"5 4"7 6"5 3"5 47 IV 5-9 -5"9 2'9 20 IV 6-5 -6-5 -53 IV 6.5 -5-9 -41 V 6.5 -6-5 2.9 B-1 V 5.9 -5.9 -71 VI 5.9 4-7 5'3 -31 VI 6.5 5-9 5.9 -E- To examine the role of disulphide bonds or threedimensional structure in antigenicity, the ELISA antigen was treated with 2-ME or SDS. The MAbs to five sites (sites I, III, IV, V and VII) on H exhibited significantly lower titres in ELISA with 2-ME-treated than with untreated antigen, whereas the remaining anti-H MAbs (sites II and VI) and all the anti-F MAbs reacted with both. In contrast, all the MAbs, except for MAb 100, showed reduced reactivity in ELISA when antigen had been treated with SDS (Table 5 ). These results indicated that the antigenic sites on H and F are dependent on conformation.
Discussion
An understanding of the functional and antigenic properties of viral surface glycoproteins is important for the development of a recombinant vaccine to control rinderpest; we had previously characterized four RPV structural proteins, including H and F (Sugiyama et aL, 1989) . The present report examines the antigenic structure and functional characterization of the H and F molecules, and provides a more complete picture of the antigenic variation in the envelope proteins of other morbilliviruses.
The competitive binding assay indicates that RPV-H has at least seven distinct antigenic sites and one bridge site. Of these sites, six were able to induce neutralizing activity. Similar results have been reported for H of other morbilliviruses, i.e. two of three sites of MV-H (Sato et al., 1985) and six of seven sites of CDV-H (Orvell et al., 1985) . Therefore, we suggest that neutralizing epitopes are present in much of the antigenic domain of the H proteins of morbilliviruses. The neutralizing activity of the MAbs to non-neutralizing or weakly neutralizing sites can be enhanced by complement. Although the mechanism responsible for this enhancement is not known, successful immunization with a recombinant vaccinia virus expressing RPV-H may be partly dependent on this mechanism Tsukiyama et al., 1989) .
The HI activity of the anti-H MAbs to site V may be related to the fact that only this site is completely conserved among morbilliviruses. Waterson et al. (1963) reported that MV treated with ether and Tween 80 shares common haemagglutinating antigens with RPV and CDV. Our results indicate that there is antigenic similarity between these viruses.
Of the morbillivirus structural proteins, data from studies using MAbs have shown H to be the most distinct (Sheshberadaran et al., 1986) and anti-H MAbs to conserved sites have not been described. In this study, only one (site V) of seven sites on H is conserved completely. When the amino acid sequences deduced from the nucleotide sequences of the RPV and MV H genes are compared (Tsukiyama et al., 1987; Yamanaka et al., 1988) , one hydrophilic region (amino acids 87 to 155) is highly conserved, although the amino acid divergence between the two viruses is about 40~. It is possible that site V may be present within this conserved region of H.
There was a moderate degree of antigenic variation in the RPV-specific sites of H of the L and RBOK strains. Yamanaka et al. (1988) indicated that H of L and Kabete O strains (Plowright & Ferris, 1959) , from which the RBOK strain was derived, differed in 12.2~ of their amino acid residues. The present results may have some relationship to this difference.
The epitopes of F have been shown to be mainly group-specific among morbilliviruses (Sheshberadaran et al., 1986) . In the present study, two sites on RPV-F were relatively conserved between RPV and MV, whereas the remaining site was unique to RPV. Similarly, one of four sites on MV-F was reported to cross-react with RPV (Sato et al., 1985) . These findings may indicate that the similarity between RPV-F and MV-F is greater than that between CDV-F and MV-F, in agreement with amino acid sequence data Rima, 1989) .
One anti-F MAb (100) reacted weakly with the surface of RPV-infected cells, precipitated the F0 protein and exhibited a significantly higher titre with SDS-treated than with untreated antigen in ELISA. This antibody may be directed to a sequential epitope of the Fo precursor, which exists before post-translational conformational changes occur, and this antibody will be useful as a tool for understanding the processing of RPV-F.
We have attempted to define whether the structural basis of the formation of antigenic determinants on RPV-H and -F is dependent on sugar moieties and protein conformation. All MAbs against RPV-H and -F reacted with the TM-treated protein. This result suggests that the defined antigenic sites are independent of Nlinked oligosaccharide chains.
The anti-H MAbs precipitated both the H apoprotein and a 54K protein, which corresponds to the nonglycosylated F0 protein, from cells treated with TM. Similar findings have been reported for Newcastle disease virus proteins after treatment with TM: coprecipitation of a 52K or 56K protein with non-glycosylated haemagglutinin-neuraminidase (HN) was observed in RIPA using anti-HN MAbs and extracts of TM-treated cells (Long et al., 1986; Nishikawa et al., 1986) . It has been suggested that this coprecipitation might be due to interaction of the 52K protein, the presumed nonglycosylated precursor of F, with regions on the nonglycosylated HN protein that are not available on native HN (Long et al., 1986) .
Treatment with 2-ME destroyed the antigenicity of five of the seven sites on RPV-H, but none of the sites on RPV-F. There are known to be 13 and 10 cysteine residues in H and F, respectively (Tsukiyama et al., 1987 (Tsukiyama et al., , 1988 , which could form disulphide bridges. In this study, all the epitopes on the envelope proteins of RPV were sensitive to SDS, indicating that disulphide bonds or three-dimensional structure is important to the antigenicity of the H and F molecules of RPV. Antigenic sites on the nucleoprotein (NP) of MV expressed in Escherichia coil have been localized using MAbs, but similar studies on H and F were not successful (Buckland et al., 1989) . The authors account for this difference by hypothesizing that the epitopes on H and F are conformation-dependent and those on NP are linear. Moreover, M~ikel/i et al. (1989) have shown that the small peptides synthesized bear little resemblance to natural antigenic sites from analysis of MV-H at the molecular level. Therefore, it appears likely that antigenic sites on the envelope proteins of morbilliviruses are not predominantly dependent on the primary amino acid sequence, but require post-translational conformational changes.
